Edgemont Capital Partners

High costs and recruitment issues drive the globalization of clinical trials

Monday, August 21, 2017

The pursuit of global trials is increasing. A report by SCORR Marketing and Applied Clinical Trials examined the reasons why companies are pursuing global clinical trials and the challenges they face in conducting them. The top two reasons cited in the survey for trials exiting the U.S. and Western Europe and moving to other regions were high costs and  patient recruitment difficulty.

[Read More]

Preparing sites for post-acquisition integration

Tuesday, August 1, 2017

The seemingly endless number of tasks required to sell a clinical research site often means there isn’t enough attention focused on what happens after the deal closes. Successful post-acquisition integration can be one of the most challenging, yet important, parts of an M&A process.

[Read More]

Preparing sites for acquisition

Saturday, July 1, 2017

The unprecedented level of M&A activity in the clinical research site sector during the past 24 months has spurred many investigative site owners to consider selling their businesses.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

Millennials accelerate seismic shift in clinical operations

Saturday, April 1, 2017

As the largest age demographic in the U.S., Millennials are dramatically reshaping the clinical research industry. Millennials have high expectations about technology, convenience and data transparency—traits that are catalyzing a trend toward decentralization and prompting industry leaders to carve out new roles in clinical trial management.

[Read More]

A cautiously optimistic healthcare M&A outlook for 2017

Monday, February 13, 2017

Although 2016 was a lackluster year for megadeals in healthcare, a recent flurry of big deals has Wall Street investors cautiously optimistic that 2017 will bring new mergers and big-ticket acquisitions. An increasingly competitive landscape in healthcare, coupled with signs that the new U.S. presidential administration may usher in more business-friendly policies, could spur major deals in the upcoming year.

[Read More]